Concepts (260)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Organ Failure | 15 | 2021 | 144 | 3.350 |
Why?
|
| Plasma Exchange | 11 | 2024 | 83 | 2.150 |
Why?
|
| Sepsis | 15 | 2024 | 496 | 2.070 |
Why?
|
| Disseminated Intravascular Coagulation | 6 | 2020 | 66 | 1.530 |
Why?
|
| Thrombocytopenia | 7 | 2020 | 221 | 1.340 |
Why?
|
| von Willebrand Factor | 10 | 2023 | 192 | 1.160 |
Why?
|
| ADAM Proteins | 6 | 2023 | 84 | 1.160 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 5 | 2021 | 157 | 0.920 |
Why?
|
| Endotoxemia | 3 | 2024 | 54 | 0.830 |
Why?
|
| Thrombosis | 6 | 2022 | 497 | 0.790 |
Why?
|
| Shock, Septic | 7 | 2020 | 149 | 0.730 |
Why?
|
| Critical Illness | 10 | 2024 | 615 | 0.690 |
Why?
|
| Critical Care | 9 | 2021 | 681 | 0.670 |
Why?
|
| Hemolytic-Uremic Syndrome | 3 | 2020 | 32 | 0.670 |
Why?
|
| Plasmapheresis | 2 | 2012 | 31 | 0.600 |
Why?
|
| Biliary Tract Diseases | 1 | 2018 | 33 | 0.570 |
Why?
|
| ADAMTS13 Protein | 7 | 2023 | 66 | 0.540 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 2 | 2015 | 52 | 0.510 |
Why?
|
| Pediatrics | 7 | 2020 | 1241 | 0.500 |
Why?
|
| Hemodynamics | 6 | 2020 | 813 | 0.500 |
Why?
|
| Liver Transplantation | 5 | 2026 | 1132 | 0.480 |
Why?
|
| Partial Thromboplastin Time | 2 | 2026 | 55 | 0.470 |
Why?
|
| Extracorporeal Membrane Oxygenation | 4 | 2024 | 683 | 0.460 |
Why?
|
| Life Support Systems | 1 | 2015 | 5 | 0.460 |
Why?
|
| Liver Diseases | 1 | 2018 | 382 | 0.420 |
Why?
|
| Whole Blood Coagulation Time | 1 | 2014 | 13 | 0.420 |
Why?
|
| Factor Xa | 1 | 2014 | 15 | 0.420 |
Why?
|
| Respiration, Artificial | 3 | 2023 | 503 | 0.390 |
Why?
|
| Heparin | 1 | 2014 | 206 | 0.380 |
Why?
|
| Blood Coagulation Disorders | 2 | 2013 | 105 | 0.370 |
Why?
|
| Child, Preschool | 23 | 2026 | 15004 | 0.350 |
Why?
|
| Infant | 24 | 2026 | 13306 | 0.350 |
Why?
|
| Child | 29 | 2026 | 26199 | 0.350 |
Why?
|
| Polyethylene Glycols | 2 | 2024 | 235 | 0.340 |
Why?
|
| Peptide Fragments | 1 | 2015 | 686 | 0.340 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2012 | 190 | 0.340 |
Why?
|
| Drug Monitoring | 1 | 2014 | 285 | 0.330 |
Why?
|
| Coinfection | 1 | 2012 | 190 | 0.330 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2011 | 50 | 0.320 |
Why?
|
| Intensive Care Units, Pediatric | 6 | 2019 | 494 | 0.320 |
Why?
|
| Anticoagulants | 2 | 2014 | 600 | 0.310 |
Why?
|
| Ferritins | 2 | 2021 | 108 | 0.300 |
Why?
|
| Staphylococcus aureus | 1 | 2012 | 481 | 0.290 |
Why?
|
| Humans | 50 | 2026 | 130921 | 0.290 |
Why?
|
| Guidelines as Topic | 2 | 2020 | 201 | 0.290 |
Why?
|
| Acute Kidney Injury | 1 | 2015 | 689 | 0.270 |
Why?
|
| Biliary Atresia | 2 | 2023 | 221 | 0.270 |
Why?
|
| Staphylococcal Infections | 1 | 2012 | 564 | 0.270 |
Why?
|
| Influenza, Human | 1 | 2012 | 702 | 0.240 |
Why?
|
| Hemorrhage | 2 | 2024 | 501 | 0.240 |
Why?
|
| Cardiomyopathies | 2 | 2023 | 517 | 0.240 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 1299 | 0.240 |
Why?
|
| Citrulline | 2 | 2024 | 123 | 0.230 |
Why?
|
| Thrombelastography | 1 | 2026 | 66 | 0.220 |
Why?
|
| Liver Failure | 1 | 2026 | 99 | 0.220 |
Why?
|
| Hydrolases | 2 | 2024 | 61 | 0.220 |
Why?
|
| Blood Loss, Surgical | 1 | 2026 | 169 | 0.220 |
Why?
|
| Drowning | 1 | 2025 | 47 | 0.210 |
Why?
|
| Male | 23 | 2026 | 64807 | 0.210 |
Why?
|
| Nervous System Diseases | 2 | 2025 | 397 | 0.200 |
Why?
|
| Adolescent | 14 | 2026 | 20838 | 0.200 |
Why?
|
| Resuscitation | 4 | 2020 | 280 | 0.200 |
Why?
|
| Female | 22 | 2026 | 70722 | 0.190 |
Why?
|
| Biomarkers | 5 | 2017 | 3405 | 0.190 |
Why?
|
| Fibrin | 3 | 2022 | 64 | 0.190 |
Why?
|
| Lipopolysaccharides | 3 | 2024 | 303 | 0.190 |
Why?
|
| Arginine | 2 | 2024 | 335 | 0.180 |
Why?
|
| Platelet Adhesiveness | 2 | 2015 | 36 | 0.180 |
Why?
|
| Retrospective Studies | 13 | 2026 | 17678 | 0.170 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2021 | 18 | 0.170 |
Why?
|
| HLA-DR Antigens | 1 | 2021 | 64 | 0.170 |
Why?
|
| Thromboembolism | 1 | 2022 | 92 | 0.170 |
Why?
|
| Membrane Glycoproteins | 2 | 2021 | 418 | 0.170 |
Why?
|
| Disease Models, Animal | 3 | 2024 | 4665 | 0.170 |
Why?
|
| Patient Discharge | 1 | 2025 | 510 | 0.170 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2025 | 338 | 0.170 |
Why?
|
| Emergency Medical Services | 1 | 2025 | 420 | 0.160 |
Why?
|
| Macrophage Activation Syndrome | 2 | 2017 | 10 | 0.160 |
Why?
|
| Extracorporeal Circulation | 2 | 2018 | 46 | 0.160 |
Why?
|
| Blood Coagulation Tests | 2 | 2026 | 66 | 0.160 |
Why?
|
| Perioperative Care | 1 | 2021 | 216 | 0.150 |
Why?
|
| Liver Cirrhosis | 3 | 2023 | 908 | 0.150 |
Why?
|
| End Stage Liver Disease | 1 | 2021 | 191 | 0.150 |
Why?
|
| Lymphocyte Activation | 1 | 2021 | 627 | 0.150 |
Why?
|
| Thromboplastin | 2 | 2016 | 19 | 0.150 |
Why?
|
| Tracheostomy | 1 | 2021 | 215 | 0.140 |
Why?
|
| Phenotype | 2 | 2020 | 4482 | 0.140 |
Why?
|
| Gene Expression Regulation | 1 | 2007 | 2341 | 0.140 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 461 | 0.140 |
Why?
|
| Catheterization, Central Venous | 1 | 2019 | 142 | 0.130 |
Why?
|
| Endothelial Cells | 2 | 2023 | 515 | 0.130 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 169 | 0.130 |
Why?
|
| Infant, Newborn | 8 | 2024 | 8556 | 0.130 |
Why?
|
| Patient Care Bundles | 1 | 2017 | 23 | 0.130 |
Why?
|
| Acute-On-Chronic Liver Failure | 1 | 2018 | 73 | 0.130 |
Why?
|
| Renal Replacement Therapy | 1 | 2018 | 162 | 0.120 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2017 | 112 | 0.120 |
Why?
|
| Cause of Death | 1 | 2018 | 511 | 0.120 |
Why?
|
| Recombinant Proteins | 2 | 2021 | 1318 | 0.120 |
Why?
|
| Endothelium | 1 | 2016 | 62 | 0.120 |
Why?
|
| Shiga Toxins | 1 | 2015 | 2 | 0.120 |
Why?
|
| Complement Inactivating Agents | 1 | 2015 | 12 | 0.120 |
Why?
|
| Hemostasis | 1 | 2016 | 76 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 365 | 0.120 |
Why?
|
| Organ Dysfunction Scores | 3 | 2020 | 53 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 376 | 0.110 |
Why?
|
| Complement System Proteins | 1 | 2015 | 57 | 0.110 |
Why?
|
| Vasoconstrictor Agents | 3 | 2020 | 137 | 0.110 |
Why?
|
| Case-Control Studies | 2 | 2021 | 3422 | 0.110 |
Why?
|
| Disease Progression | 2 | 2018 | 2206 | 0.110 |
Why?
|
| Risk Factors | 4 | 2023 | 10997 | 0.110 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2014 | 67 | 0.110 |
Why?
|
| Fluid Therapy | 3 | 2020 | 145 | 0.100 |
Why?
|
| Models, Statistical | 1 | 2016 | 486 | 0.100 |
Why?
|
| Risk Assessment | 3 | 2016 | 3711 | 0.100 |
Why?
|
| Severity of Illness Index | 3 | 2024 | 3065 | 0.100 |
Why?
|
| Evidence-Based Medicine | 2 | 2020 | 642 | 0.100 |
Why?
|
| Inflammation Mediators | 1 | 2015 | 229 | 0.100 |
Why?
|
| Fibrinogen | 3 | 2026 | 165 | 0.100 |
Why?
|
| Prognosis | 4 | 2017 | 4953 | 0.090 |
Why?
|
| Medical Audit | 1 | 2012 | 96 | 0.090 |
Why?
|
| Logistic Models | 2 | 2025 | 1826 | 0.090 |
Why?
|
| Animals | 9 | 2024 | 33954 | 0.090 |
Why?
|
| Catheterization, Peripheral | 1 | 2013 | 127 | 0.090 |
Why?
|
| Treatment Outcome | 5 | 2025 | 12933 | 0.090 |
Why?
|
| Mitochondria | 1 | 2017 | 767 | 0.090 |
Why?
|
| Protein Binding | 1 | 2015 | 1666 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2015 | 576 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 2 | 2023 | 4707 | 0.080 |
Why?
|
| Respiratory Insufficiency | 1 | 2013 | 241 | 0.080 |
Why?
|
| Predictive Value of Tests | 2 | 2026 | 2311 | 0.080 |
Why?
|
| Diagnosis, Differential | 3 | 2021 | 1902 | 0.080 |
Why?
|
| Survival Rate | 2 | 2019 | 2150 | 0.080 |
Why?
|
| Swine | 2 | 2024 | 1188 | 0.070 |
Why?
|
| Lung Diseases | 1 | 2013 | 403 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2012 | 1248 | 0.070 |
Why?
|
| ROC Curve | 2 | 2026 | 613 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 3425 | 0.070 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2008 | 62 | 0.070 |
Why?
|
| Cell Adhesion | 1 | 2008 | 305 | 0.070 |
Why?
|
| Societies, Medical | 1 | 2012 | 791 | 0.070 |
Why?
|
| United States | 5 | 2017 | 11814 | 0.070 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 431 | 0.070 |
Why?
|
| Glutathione | 1 | 2008 | 198 | 0.070 |
Why?
|
| Consensus | 2 | 2020 | 529 | 0.070 |
Why?
|
| Reference Values | 1 | 2008 | 684 | 0.060 |
Why?
|
| Heart Defects, Congenital | 1 | 2019 | 1907 | 0.060 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2007 | 50 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2008 | 951 | 0.060 |
Why?
|
| Mice | 3 | 2023 | 18235 | 0.060 |
Why?
|
| Interferon-gamma | 2 | 2021 | 541 | 0.060 |
Why?
|
| Protein C | 1 | 2006 | 17 | 0.060 |
Why?
|
| International Normalized Ratio | 1 | 2026 | 45 | 0.060 |
Why?
|
| Child Mortality | 1 | 2005 | 23 | 0.060 |
Why?
|
| Swimming Pools | 1 | 2025 | 12 | 0.060 |
Why?
|
| Blood Coagulation | 1 | 2026 | 133 | 0.060 |
Why?
|
| Platelet Count | 2 | 2016 | 140 | 0.060 |
Why?
|
| Interleukin-6 | 1 | 2007 | 416 | 0.050 |
Why?
|
| Pandemics | 2 | 2024 | 1160 | 0.050 |
Why?
|
| Inflammation | 2 | 2024 | 1493 | 0.050 |
Why?
|
| Patient Transfer | 1 | 2005 | 111 | 0.050 |
Why?
|
| Neurologic Examination | 1 | 2025 | 187 | 0.050 |
Why?
|
| Infant Mortality | 1 | 2005 | 184 | 0.050 |
Why?
|
| Medical Order Entry Systems | 1 | 2005 | 108 | 0.050 |
Why?
|
| Acute Disease | 1 | 2007 | 1153 | 0.050 |
Why?
|
| Propofol | 1 | 2003 | 48 | 0.050 |
Why?
|
| Urban Population | 1 | 2025 | 277 | 0.050 |
Why?
|
| Hospital Mortality | 3 | 2017 | 1073 | 0.050 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 1250 | 0.050 |
Why?
|
| Syndrome | 1 | 2006 | 1162 | 0.050 |
Why?
|
| GTP-Binding Proteins | 1 | 2023 | 161 | 0.050 |
Why?
|
| Time Factors | 3 | 2019 | 6250 | 0.050 |
Why?
|
| Hypnotics and Sedatives | 1 | 2003 | 132 | 0.050 |
Why?
|
| Fibrinolysis | 1 | 2022 | 43 | 0.050 |
Why?
|
| Age Factors | 1 | 2008 | 2848 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2025 | 1231 | 0.040 |
Why?
|
| Bile Acids and Salts | 1 | 2023 | 259 | 0.040 |
Why?
|
| Biological Availability | 1 | 2021 | 140 | 0.040 |
Why?
|
| Heart Arrest | 1 | 2025 | 379 | 0.040 |
Why?
|
| Oxidoreductases | 1 | 2021 | 103 | 0.040 |
Why?
|
| Algorithms | 2 | 2020 | 1678 | 0.040 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2021 | 103 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2021 | 365 | 0.040 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 205 | 0.040 |
Why?
|
| Adult | 3 | 2024 | 31326 | 0.040 |
Why?
|
| Proteome | 1 | 2021 | 287 | 0.040 |
Why?
|
| Lactic Acid | 1 | 2020 | 148 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2008 | 5236 | 0.040 |
Why?
|
| Attitude to Health | 1 | 2020 | 247 | 0.040 |
Why?
|
| Kinetics | 1 | 2021 | 1090 | 0.040 |
Why?
|
| Central Venous Catheters | 1 | 2019 | 51 | 0.040 |
Why?
|
| Cytokines | 1 | 2024 | 1346 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2018 | 91 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2021 | 1520 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 286 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 2020 | 265 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2019 | 6496 | 0.030 |
Why?
|
| Chemokine CCL3 | 1 | 2016 | 17 | 0.030 |
Why?
|
| Matrix Metalloproteinase 8 | 1 | 2016 | 15 | 0.030 |
Why?
|
| Granzymes | 1 | 2016 | 47 | 0.030 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2019 | 358 | 0.030 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2016 | 72 | 0.030 |
Why?
|
| Cardiovascular Agents | 1 | 2017 | 86 | 0.030 |
Why?
|
| Texas | 1 | 2025 | 3630 | 0.030 |
Why?
|
| Glycocalyx | 1 | 2016 | 5 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2016 | 206 | 0.030 |
Why?
|
| Young Adult | 2 | 2021 | 10029 | 0.030 |
Why?
|
| Research Design | 1 | 2020 | 715 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2016 | 398 | 0.030 |
Why?
|
| NADPH Oxidase 2 | 1 | 2014 | 37 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2017 | 370 | 0.030 |
Why?
|
| Fungemia | 1 | 2014 | 21 | 0.030 |
Why?
|
| beta-Glucans | 1 | 2014 | 20 | 0.030 |
Why?
|
| Granulocytes | 1 | 2014 | 68 | 0.030 |
Why?
|
| Proteoglycans | 1 | 2014 | 77 | 0.030 |
Why?
|
| Anesthesia | 1 | 2017 | 209 | 0.030 |
Why?
|
| Fever of Unknown Origin | 1 | 2014 | 43 | 0.030 |
Why?
|
| Immunization, Passive | 1 | 2014 | 122 | 0.030 |
Why?
|
| Opportunistic Infections | 1 | 2014 | 71 | 0.030 |
Why?
|
| NADPH Oxidases | 1 | 2014 | 108 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2016 | 655 | 0.030 |
Why?
|
| Catheter Obstruction | 1 | 2013 | 8 | 0.030 |
Why?
|
| Prothrombin Time | 1 | 2013 | 36 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2016 | 827 | 0.020 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2013 | 39 | 0.020 |
Why?
|
| Length of Stay | 1 | 2019 | 1398 | 0.020 |
Why?
|
| Autopsy | 1 | 2013 | 119 | 0.020 |
Why?
|
| Echocardiography | 1 | 2019 | 1138 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2016 | 467 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 3817 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2014 | 791 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2013 | 322 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2016 | 382 | 0.020 |
Why?
|
| Incidence | 1 | 2019 | 3348 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 662 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2013 | 518 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2019 | 5092 | 0.020 |
Why?
|
| Protein Multimerization | 1 | 2010 | 149 | 0.020 |
Why?
|
| Antigens, Human Platelet | 1 | 2008 | 6 | 0.020 |
Why?
|
| Glutathione Disulfide | 1 | 2008 | 20 | 0.020 |
Why?
|
| Hemorheology | 1 | 2008 | 25 | 0.020 |
Why?
|
| Integrin beta3 | 1 | 2008 | 28 | 0.020 |
Why?
|
| Cricetulus | 1 | 2008 | 88 | 0.020 |
Why?
|
| CHO Cells | 1 | 2008 | 148 | 0.020 |
Why?
|
| Pulsatile Flow | 1 | 2008 | 112 | 0.020 |
Why?
|
| Cricetinae | 1 | 2008 | 364 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 2127 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 2557 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2008 | 177 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2008 | 432 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2008 | 419 | 0.020 |
Why?
|
| Umbilical Veins | 1 | 2007 | 63 | 0.020 |
Why?
|
| Transfection | 1 | 2008 | 955 | 0.020 |
Why?
|
| Microcirculation | 1 | 2007 | 106 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2007 | 812 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2007 | 468 | 0.010 |
Why?
|
| Contraindications | 1 | 2003 | 77 | 0.010 |
Why?
|
| United States Food and Drug Administration | 1 | 2003 | 154 | 0.010 |
Why?
|
| Safety | 1 | 2003 | 215 | 0.010 |
Why?
|
| Fatty Acids | 1 | 2003 | 379 | 0.010 |
Why?
|